Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phibro Animal Health Corporation filings document current reports for an animal health and mineral nutrition operating company with Class A common stock registered on Nasdaq. Recent Form 8-K disclosures cover operating results and financial guidance, quarterly dividends on Class A and Class B common stock, and amendments to the company’s credit agreement.
The filing record also includes Regulation FD disclosure about Brazilian rules for performance enhancing feed additives containing antimicrobials, including virginiamycin and bacitracin, and governance reports covering board and executive leadership changes. These filings frame PAHC’s disclosure record around operating performance, capital allocation, debt capacity, product regulation and public-company governance.
Phibro Animal Health Corporation describes a new Brazilian rule that will phase out growth-promotion uses of certain antimicrobial feed additives, including its virginiamycin and bacitracin products. Brazil’s Ministry of Agriculture and Livestock published Ordinance No. 1617, which bans the import, manufacture, marketing and use of these performance-enhancing additives.
The prohibition takes effect after a 180-day transition period, during which current products and labels may still be used and sold. Phibro is pursuing new registrations of virginiamycin for therapeutic use in cattle and broiler chickens and notes its bacitracin product already has therapeutic claims in Brazil. Under the new framework, future use of these antimicrobials will require a veterinary prescription, and Phibro is introducing its PhibroVet digital platform in Brazil to help manage prescriptions. The company expects this regulatory change to have limited impact on its fiscal year 2026 results and plans to provide further detail on its May 7, 2026 earnings call.
BFI Co., LLC and Jack C. Bendheim report updated ownership of Phibro Animal Health Corporation Class A Common Stock in an Amendment No. 24 to Schedule 13D. They beneficially own 19,591,914 shares of Common Stock, representing 48.3% of the Class A Common Stock on an as-converted basis.
BFI directly holds 95,880 shares of Class A Common Stock and 19,496,034 shares of Class B Common Stock, which is convertible into Class A on a one-for-one basis and carries ten votes per share. The filing notes market disposals of Class A shares within the prior 60 days, detailed in an exhibit.
Phibro Animal Health reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open‑market transactions at weighted average prices around $54–$56 per share. These sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025. After the sales, BFI Co., LLC held 95,880 Class A shares, while Jack Bendheim directly held 16,840 Class A shares.
Phibro Animal Health Corp’s CEO-linked entity BFI Co., LLC converted 100,000 shares of Class B Common Stock into 100,000 shares of Class A Common Stock and then sold 21,120 Class A shares in open-market transactions from April 14–16 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices ranged from about $53.80 to $59.83. After these trades, BFI held 117,000 Class A shares indirectly, while Jack Bendheim also directly held 16,840 Class A shares, showing that a substantial position remains after these planned sales.
Phibro Animal Health Corporation reported that board member Joyce J. Lee, a Class II Director, informed the company on April 13, 2026 that she intends to resign from the Board effective April 15, 2026. The company stated that Ms. Lee’s resignation is not due to any disagreement regarding its operations, policies, or practices.
FMR LLC reported beneficial ownership of 2,173,126.20 shares of PHIBRO ANIMAL HEALTH CORP Class A common stock, representing 10.5% of the class as of 03/31/2026. The filing states FMR has sole voting power over 2,171,187 shares and sole dispositive power over 2,173,126.20 shares. The Schedule 13G notes some shares are held on behalf of other persons and refers to Exhibit 99 for a 13d-1(k)(1) agreement.
Phibro Animal Health (PAHC) insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI Co., LLC reported open-market sales totaling 14,080 shares of Class A Common Stock on March 30 and March 31 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices were about $53.54 and $54.31 per share on March 30 and about $53.87 and $54.35 per share on March 31. After these transactions, BFI Co., LLC holds 38,120 shares indirectly, while Bendheim directly holds 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health Corp (PAHC) filing shows The Vanguard Group filed Amendment No. 13 to its Schedule 13G/A stating it beneficially owns 0% of Phibro Animal Health Corp common stock as reported in the form. The amendment explains an internal realignment on 01/12/2026 that caused certain Vanguard subsidiaries and business divisions to report ownership separately.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity over which President and CEO Jack Bendheim exercises voting and dispositive power, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on March 24–26, 2026.
The weighted average sale prices ranged from about $52.8772 to $57.1702 per share. Following these indirect sales, BFI Co., LLC held 52,200 Class A shares, while Bendheim directly held 16,840 shares. The sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating they were pre-scheduled rather than discretionary.
Phibro Animal Health insider activity shows an entity associated with President and CEO Jack Bendheim selling Class A Common Stock. BFI Co., LLC sold a total of 22,880 shares in open-market transactions on March 17–19 at reported weighted average prices between $51.6590 and $53.6436 per share, under a Rule 10b5-1 trading plan adopted on December 11, 2025. Following these sales, BFI Co., LLC held 73,320 shares indirectly, while Jack Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.